cancer-therapy-and-biomarkers-2016_tracks-abstracts

3 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 25
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Overcoming therapy-resistant cancer stem cells
Hideshi Ishii
Osaka University Graduate School of Medicine, Japan
Till date, international pharmaceutical companies have produced numerous anti-cancer reagents, including molecular tar-
geting strategies and immunotherapies, but resistance exists even for these up-to-date medicines. The most important
factors that make present therapeutic strategies ineffective are tumor heterogeneities. To visualize and collect cancer stem cell
fractions, we transfected cancer cells with a green fluorescent protein-fusion one-carbon metabolism monitoring cassette. The
monitoring system allowed visualization of cancer cell populations with therapy-resistant cancer stem cell properties. The pres-
ent study revealed that polyamine flux plays a critical role in cancer stem cell properties, and polyamine metabolism is linked
with epigenetic regulation of downstream gene expression. Epigenetic studies demonstrated the uncharacterized mechanism
of transcription cycles and underscored the significance of molecular profiling in the discovery of novel therapeutic targets for
retractable cancer cells. These novel approaches are beneficial for cancer research and may open avenues for treating gastroin-
testinal cancers that present challenges for treatment.
Biography
Ishii has completed his postdoctoral studies from Thomas Jefferson University, Philadelphia, PA. He is the professor of cancer profiling discovery, Osaka University,
Japan. Specialty and Present Interest: intractable cancer stem cells, epigenome, metabolome, gastrointestinal tumors.
Hideshi Ishii, Oncol Cancer Case Rep 2016,2:3(Suppl)